What is Gemini Therapeutics, Inc. (GMTX) stock price today?

Gemini Therapeutics, Inc. (GMTX) is currently trading at $1.35, up 0% today.

What is GMTX P/E ratio?

Gemini Therapeutics, Inc.'s P/E ratio is -0.22. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GMTX return on equity (ROE)?

Gemini Therapeutics, Inc.'s return on equity (ROE) is -28.65%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Gemini Therapeutics, Inc.'s market cap?

Gemini Therapeutics, Inc. has a market capitalization of $25.49M.

NASDAQ · Biotechnology

Gemini Therapeutics, Inc. (GMTX) Stock

$1.35 +0.00% NASDAQ: GMTX Healthcare

Valuation

Metric	Value
Price	$1.35
Market Cap	$25.49M
P/E Ratio	-0.22
P/B Ratio	0.03
P/S Ratio	—
EPS (TTM)	$-6.01
52-Week High	$24.70
52-Week Low	$1.35
Dividend Yield	—

Financials & Margins

Metric	Value
ROE	-28.65%
ROA	-26.27%
ROCE	-30.65%
Gross Margin	—
Operating Margin	—
Net Margin	—
Debt/Equity	0.04
Current Ratio	21.73

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	—	—	—	—	—
Operating Profit	$-31.0M	$-47.0M	$-91.0M	$-130.0M	$-236.0M
Net Profit	$-36.0M	$-47.0M	$-76.0M	$-109.0M	$-212.0M
EPS	$-40.95	$-45.05	$-3.42	$-3.96	$-6.01
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$92.0M	$200.0M	$368.0M	$497.0M	$807.0M
Total Liabilities	$15.0M	$24.0M	$23.0M	$53.0M	$67.0M
Cash	$88.0M	$195.0M	$360.0M	$192.0M	$91.0M
Borrowings	$14.0M	$14.0M	—	$28.0M	$29.0M

Latest News

OP Pohjola's President and Group CEO Timo Ritakallio has announced that he will retire on 1 July 2027 as specified in his executive contract GlobeNewswire · Jul 23, 2026 Tocvan Discovers New High-Grade At-Surface Silver-Gold Zone 900 m East of Pilot Facility at Gran Pilar Project ACCESS Newswire · Jul 23, 2026 Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 Eco (Atlantic) Oil and Gas Ltd Announces Audited Results for the Year Ended 31 March 2026 ACCESS Newswire · Jul 23, 2026 OP Corporate Bank plc's Half-year Financial Report 1 January–30 June 2026 GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-28.0M	$-42.0M	$-73.0M	$-94.0M	$-180.0M
Investing Cash Flow	$0	$0	$0	$-292.0M	$-394.0M
Financing Cash Flow	$90.0M	$149.0M	$239.0M	$218.0M	$473.0M
Net Cash Flow	$62.0M	$107.0M	$166.0M	$-168.0M	$-101.0M
Free Cash Flow	$-28.0M	$-42.0M	$-74.0M	$-94.0M	$-181.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-710.03%
Quick Ratio	21.73
Interest Coverage	-118.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLKAllakos Inc.	$0.33	+0.22%	-0.25	$29.74M	0.00%
ANGNAngion Biomedica Corp.	$1.00	+0.00%	-0.42	$30.11M	0.00%
ANPCAnPac Bio-Medical Science Co., Ltd.	$4.30	-3.15%	-0.54	$26.97M	0.00%
ELEVElevation Oncology, Inc.	$0.37	-2.12%	-0.47	$21.63M	0.00%
FRLNFreeline Therapeutics Holdings plc	$6.49	+0.15%	-0.29	$28.28M	0.00%

About Gemini Therapeutics, Inc.

Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.

Gemini Therapeutics, Inc. is headquartered in US.

Gemini Therapeutics, Inc. (GMTX) stock trades at $1.35 with a market capitalization of $25.49M. The stock is valued at a price-to-earnings (P/E) ratio of -0.22, price-to-book of 0.03. Over the past 52 weeks the stock has ranged between $1.35 and $24.70, and currently trades 94.5% below its 52-week high.

On profitability, Gemini Therapeutics, Inc. generates a return on equity (ROE) of -28.65%, return on capital employed of -30.65%.

Official website: www.geminitherapeutics.com